Omeros (NASDAQ:OMER) Stock Price Up 7.8% - What's Next?

Omeros Co. (NASDAQ:OMER - Get Free Report) shares shot up 7.8% on Friday . The company traded as high as $11.99 and last traded at $11.97. 162,021 shares were traded during trading, a decline of 68% from the average session volume of 508,536 shares. The stock had previously closed at $11.10.

Analyst Ratings Changes

A number of research firms have recently weighed in on OMER. Rodman & Renshaw began coverage on Omeros in a report on Thursday, November 14th. They set a "buy" rating and a $9.00 price target on the stock. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a report on Thursday, November 14th. Cantor Fitzgerald reissued a "neutral" rating on shares of Omeros in a report on Thursday, November 14th. StockNews.com raised Omeros from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, RODMAN&RENSHAW raised Omeros to a "strong-buy" rating in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $9.00.

Omeros Trading Up 4.6 %

The stock has a market capitalization of $672.80 million, a PE ratio of -5.03 and a beta of 1.97. The firm's 50-day simple moving average is $6.05 and its two-hundred day simple moving average is $4.80.

Institutional Investors Weigh In On Omeros

Several institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its position in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 7,016 shares during the last quarter. MML Investors Services LLC lifted its position in Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company's stock worth $74,000 after acquiring an additional 3,000 shares during the last quarter. SPC Financial Inc. acquired a new position in Omeros during the 3rd quarter worth $77,000. SG Americas Securities LLC acquired a new position in Omeros during the 3rd quarter worth $80,000. Finally, Comerica Bank lifted its position in Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.